Breast Cancer Research (May 2021)
Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient
- Yuanting Zheng,
- Bingying Li,
- Dejing Pan,
- Jun Cao,
- Jian Zhang,
- Xiaolin Wang,
- Xiangnan Li,
- Wanwan Hou,
- Ding Bao,
- Luyao Ren,
- Jingcheng Yang,
- Shangzi Wang,
- Yangyang Qiu,
- Fei Zhou,
- Zhiwei Liu,
- Sibo Zhu,
- Lei Zhang,
- Tao Qing,
- Yi Wang,
- Ying Yu,
- Jiaxue Wu,
- Xichun Hu,
- Leming Shi
Affiliations
- Yuanting Zheng
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Bingying Li
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Dejing Pan
- Cambridge-Suda Genomic Resource Center and Jiangsu Key Laboratory of Neuropsychiatric Diseases Research, Soochow University
- Jun Cao
- Department of Medical Oncology, Fudan University Shanghai Cancer Center
- Jian Zhang
- Department of Medical Oncology, Fudan University Shanghai Cancer Center
- Xiaolin Wang
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Xiangnan Li
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Wanwan Hou
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Ding Bao
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Luyao Ren
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Jingcheng Yang
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Shangzi Wang
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Yangyang Qiu
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Zhongshan Hospital, Fudan University
- Fei Zhou
- Cambridge-Suda Genomic Resource Center and Jiangsu Key Laboratory of Neuropsychiatric Diseases Research, Soochow University
- Zhiwei Liu
- Cambridge-Suda Genomic Resource Center and Jiangsu Key Laboratory of Neuropsychiatric Diseases Research, Soochow University
- Sibo Zhu
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Lei Zhang
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Tao Qing
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Yi Wang
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Ying Yu
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- Jiaxue Wu
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Zhongshan Hospital, Fudan University
- Xichun Hu
- Department of Medical Oncology, Fudan University Shanghai Cancer Center
- Leming Shi
- State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University
- DOI
- https://doi.org/10.1186/s13058-021-01428-5
- Journal volume & issue
-
Vol. 23,
no. 1
pp. 1 – 7
Abstract
Abstract We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast cancer patient who later was administrated with a PARP inhibitor for 2 months. We demonstrated in cell and mouse models that, compared to the wild-type, (1) c.403G>A mutant cell lines were more sensitive to irradiation, a DNA damage agent, and a PARP inhibitor; (2) c.403G>A mutation inhibited interaction between BARD1 and RAD51 (but not BRCA1); and (3) c.403G>A mutant mice were hypersensitive to ionizing radiation. Our study shed lights on the clinical interpretation of rare germline mutations of BARD1.
Keywords
- BARD1
- Rare mutation
- c.403G>A
- p.Asp135Asn
- Integrated genomics profiling
- Triple-negative breast cancer